Quesada J R, Hersh E M, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman J U
Blood. 1986 Aug;68(2):493-7.
Thirty patients with hairy cell leukemia were treated with recombinant interferon alpha-A (rIFN alpha A; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFN alpha A was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN alpha A is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.
30例毛细胞白血病患者接受重组干扰素α-A（rIFNαA；罗扰素）治疗；7例为初治患者。经骨髓芯针活检证实9例完全缓解，17例部分缓解。所有患者的外周血细胞学指标均有所改善或恢复正常。13例有腹膜后或纵隔淋巴结肿大的患者中有12例肿瘤肿块获得缓解。所有7例脾肿大患者的脾脏大小迅速缩小至正常。初治患者（7例中的5例）的完全缓解率显著高于行脾切除术的患者（23例中的4例）（P = 0.02），这一结果推测与预处理时的肿瘤负荷有关。rIFNαA耐受性良好；最常见的主诉是轻度疲劳。在大多数患者中，肿瘤缓解导致生活质量改善：不再需要输注血液制品，感染发生率降低，部分患者的免疫缺陷明显恢复。我们得出结论，rIFNαA对毛细胞白血病的所有阶段都是一种有效的治疗方法，包括初治或新诊断的患者。
